Related Experiment Videos
[Management of chronic hepatitis B].
1Medizinische Universitätsklinik Freiburg, Abteilung II.
Praxis
|May 20, 2005
Summary
Chronic hepatitis B treatments like interferon and antivirals suppress viral replication but have drawbacks. Individualized strategies are needed due to side effects and resistance, impacting long-term hepatitis B management.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis B is a significant global health concern, leading to liver cirrhosis and hepatocellular carcinoma.
- Current treatments for chronic hepatitis B include interferon-alpha, pegylated interferon-alpha, lamivudine, and adefovir.
Purpose of the Study:
- To review the efficacy and limitations of current therapeutic options for chronic hepatitis B.
- To highlight the need for individualized treatment strategies based on patient-specific parameters.
Main Methods:
- Literature review of existing studies on chronic hepatitis B treatments.
- Analysis of efficacy, side effects, and resistance patterns of approved therapies.
Main Results:
- Interferon-alpha offers long-term viral suppression but has significant side effects.
- Lamivudine and adefovir effectively suppress viral replication and improve histology, but high recurrence rates are observed post-treatment.
- Emergence of drug-resistant mutants is a concern, with approximately 20% annual rates for lamivudine and 3% for adefovir after two years.
Conclusions:
- Current hepatitis B therapies have limitations including side effects and treatment resistance.
- Individualized treatment approaches are essential for optimizing outcomes in chronic hepatitis B management.